| abstract |
The invention concerns the use of at least one: a) a GILZ protein, a functional fragment of at least 5 consecutive amino acids of said protein, a GILZ modulator, or a recombinant vector expressing same, isolated or expressed in modified dendritic cells, and b) an antigen of interest and/or a molecule allowing targeting and/or passage of the plasmic membrane of dendritic cells, to prepare a medicine for preventing and/or treating autoimmune, inflammatory diseases, allergies, graft rejection and graft-versus-host disease, cancers and pathogenic micro-organism infections. |